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Background: Opioid use during pregnancy is a significant public health issue. The standard of care for treating
opioid use disorder during pregnancy includes medications for opioid disorder (MOUD). However, tobacco use
often goes unaddressed among pregnant women on MOUD. In 2018, our team received a National Institute on
Drug Abuse (NIDA) funded R34 to conduct a three year-randomized trial to test the feasibility of a novel tobacco
intervention for pregnant women receiving MOUD.
Aims: The aims of this study are: (1) to determine the impact of the B-EPIC intervention on maternal tobacco use
and stage of change; (2) to determine the impact of B-EPIC on tobacco-related maternal and infant health out
comes including gestational age at birth, birthweight, NAS diagnosis and severity, and number of ear and res
piratory infections during the first six months; (3) to compare healthcare utilization and costs incurred by
pregnant patients that receive the B-EPIC intervention versus TAU.
Methods: We plan to enroll 100 pregnant women on MOUD for this randomized controlled trial (B-EPIC inter
vention n = 50 and treatment as usual n = 50). A major strength of this study is its wide range of health and
economic outcomes assessed on mother, neonate and the infant.
Conclusions: Despite the very high rates of smoking among pregnant women with OUD, there are few tobacco
treatment interventions that have been tailored for this high - risk population. The overall goal of this study is to
move towards a tobacco treatment standard for pregnant women receiving treatment for OUD.

1. Introduction
Opioid use and untreated opioid dependence (Diagnostic and Sta
tistical Manual of Mental Disorder, 4th Edition, DSM 4) during preg
nancy is a significant public health issue associated with complications
such as intrauterine growth restriction, placental abruption, preterm
delivery, cesarean delivery, and stillbirth [1]. Intravenous opioid use
increases the risk of infectious diseases such as hepatitis C and endo
carditis [2], which complicate pregnancy [3,4]. As opioid use in the U.S.
has increased, there has been a dramatic increase in the prevalence of
neonatal abstinence syndrome (NAS) [5]. From 2004 to 2014, the total
healthcare costs covered by Medicaid for infants with NAS increased
from $65.4 million to $462 million [6].
The standard of care for treating opioid use disorder (OUD) during

pregnancy includes FDA-approved medication for opioid use disorder
(MOUD; also known as medication assisted treatment), including
methadone or buprenorphine. [7].According to the Substance Abuse
and Mental Health Service Administration (SAMHSA), these medica
tions help pregnant women stop injection drug use and reduce with
drawal and cravings [8]. However, tobacco use often goes unaddressed,
which is unfortunate because pregnant women in MOUD programs have
high rates of smoking (88–95%) [9,10] and smoking is an independent
risk factor for several maternal and infant adverse health outcomes [9].
For instance, smoking during pregnancy can lead to miscarriage [11],
premature birth [12], and sudden infant death syndrome [13]. In
addition to the general risks, smoking during pregnancy is associated
with higher amounts of medication needed to treat NAS, longer duration
of treatment, and longer hospital stays [14]. Smoking during pregnancy
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demonstrate greater adherence to the recommended well-child visits.
Reduced healthcare utilization associated with B-EPIC will yield a
favorable incremental cost-effectiveness ratio.

also has adverse economic consequences for families and the healthcare
system. Maternal smoking increases the risk admission to the neonatal
intensive care unit (NICU) by 19% [15], which results in significant
smoking-attributable hospital costs during the episode of delivery.
Smoking cessation has immense benefits for women and their fam
ilies over the long-term. Infants born to mothers who smoke during
pregnancy are more likely to be readmitted to the hospital during their
first year of life [16], more likely to experience asthma requiring
medication use, and are more likely to use the emergency room [17].
Further, smoking increases the risk for several women’s health issues,
including breast cancer [18], osteoporosis [19], and infertility [20].
Smoking cessation is particularly important for women with substance
use disorders, because smoking has been associated with an increased
risk of relapse [21].
Few tailored tobacco treatment interventions have been tested for
pregnant women on MOUD. Across these studies, a small percentage of
participants stopped smoking [10,22], indicating the need for a more
intense, tailored intervention for this population. One study showed
promise using an intervention that included contingency-behavioral
incentives [23], but effects of contingency incentives often cease after
the intervention period ends. Incentives are difficult to implement in
real-world clinical practice as there is no current way to reimburse for
them. Thus, there is a critical need to develop clinical care models that
incorporate feasible and effective behavioral interventions for tobacco
use among pregnant women receiving opioid use disorder treatment.
In 2018, our team received a National Institute on Drug Abuse
(NIDA) funded R34 to conduct a three year-randomized trial to test the
feasibility of a novel tobacco intervention (Behavioral and Enhanced
Perinatal Intervention for tobacco Cessation; B-EPIC) for pregnant
women receiving comprehensive buprenorphine treatment for their
OUD. The purpose of this paper is to present the B-EPIC study design,
intervention and intervention framework, and data analysis plan.

2.2. Intervention framework
We conducted two qualitative studies that provided the foundation
for the theoretical framework used to guide B-EPIC. First, our team
conducted a qualitative study to describe factors that contribute to
successful maintenance of smoking cessation during the postpartum
period among women who quit smoking during pregnancy (n = 11)
(although they did not have OUD). Primary motivators and lifestyle
characteristics of women who do not relapse to cigarette smoking [25]
for at least 6 months were investigated. Women’s narratives described
the process of postpartum smoking abstinence. Four themes emerged
and provide the basis for the holistic theoretical model Smoking Cessation
Model for Childbearing Women (Fig. 1): a) pregnancy is the primary
motivator for change; b) changes in thought processes that promote quit
attempts and help maintain abstinence; c) focus on healthy behaviors,
which may serve as healthy coping skills/replacement smoking behav
iors and prevention of smoking lapse/relapses; and d) child’s health as
primary motivator for cessation [25].
Second, we conducted a qualitative study among pregnant women
with opioid dependence (DSM 4) in an MOUD clinic who were being
treated with buprenorphine (n = 22), to assess attitudes toward smoking
cessation, facilitators and barriers to smoking cessation, and past ex
periences with smoking cessation attempts [26]. The women reported:
a) a desire to stop smoking for their health and the health of their baby,
which was similar to the previous study and provided further support for
the idea that smoking cessation interventions would be welcome by
pregnant patients receiving MOUD; b) complex barriers to cessation,
including the use of tobacco products to deal with chronic stress, which
fits into the need to develop healthy coping and relapse prevention skills
for stress; c) periodic nicotine abstinence in tobacco-free rehabilitation
facilities and in prison, which supports that abstinence is feasible; and d)
desire for intensive support for tobacco cessation, which suggested that
the intervention would need regular follow-up and opportunities for
supplemental help [22]. Lessons learned from these narrative accounts
have been integrated into the Smoking Cessation Model [21] to inform
the B-EPIC intervention, as shown in Fig 2.

2. Methods
2.1. Study aims
The study aims are to:
Aim 1. To determine the impact of the B-EPIC intervention on
maternal tobacco use and stage of change [24] during and after preg
nancy compared to the tobacco treatment as usual (TAU) control group
among women with opioid dependence receiving MOUD.

3. Study design

Hypothesis 1. The B-EPIC group will have a greater percentage of
perinatal women who quit smoking, decrease number of cigarettes
smoked per day, and/or increase their readiness to quit smoking
compared to TAU.
Aim 2. To determine the impact of B-EPIC on tobacco-related
maternal and infant health outcomes including gestational age at
birth, birthweight, NAS diagnosis and severity, and number of ear and
respiratory infections during the first six months.

3.1. Study setting and sample
The goal is to enroll and randomize 100 pregnant women receiving
MOUD treatment with buprenorphine for OUD. The study recruitment is
ongoing at two sites in Lexington, Kentucky. Recruitment began at
University of Kentucky Healthcare’s (UKHC) buprenorphine treatment
program for pregnant women with OUD, and later expanded to include
Baptist Health Lexington’s (BHL) similar prenatal buprenorphine MOUD
program.

Hypothesis 2. Women in the B-EPIC intervention will have a gesta
tional period of at least 37 weeks and their infants will experience less
severe NAS (e.g, number of days in the neonatal intensive care unit or
total mg of morphine needed to treat NAS) and fewer associated child
hood illnesses (e.g, frequency of ear and respiratory infections), and
increased number of well-child visits compared to TAU.
Aim 3: To compare healthcare utilization and costs incurred by
pregnant patients that receive the B-EPIC intervention versus TAU, with
estimates of the incremental cost-effectiveness of the B-EPIC
intervention.

3.2. Study eligibility
Planned eligibility for this study included: 1) current diagnosis of
opioid dependence (DSM 4) with participation in the UKHC integrated
prenatal care and addiction treatment program with buprenorphine
pharmacotherapy; 2) pregnant and less than 24 weeks gestation; 3) age
18–49 years old; 4) diagnosis of current tobacco use disorder; and 5)
ability to read or write in English. Women are excluded if they have
current prisoner status, diagnosed current severe mental illness, or
alcohol or sedative/hypnotic dependence that requires medical inter
vention. Given recruitment challenges, two modifications were made to
the eligibility criteria: 1) recruitment was expanded to include partici
pants in the Baptist Health Lexington integrated prenatal care and

Hypothesis 3. Infants of participants in B-EPIC will have fewer hos
pitalizations and hospital days, as well as fewer NICU admissions,
emergency department (ED) visits, and sick-child outpatient visits. As a
secondary hypothesis, we will investigate whether infants also
2
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Fig. 1. Model guiding the B-EPIC intervention based on qualitative data collection

addiction treatment program with buprenorphine pharmacotherapy,
and 2) participants of gestational age up to 32 weeks.

4.3. Tobacco treatment as usual (TAU)
Women enrolled in the TAU control group receive standard of care
from their healthcare provider, which is the American College of Ob
stetrics and Gynecology (ACOG) recommended 5 A’s approach [27] (see
Table 2). This standard takes approximately 5–15 min and is offered by
the healthcare provider at each prenatal and postpartum appointment.

4. Procedure
4.1. Recruitment
There are two methods of recruitment: 1) study flyers are posted in
highly visible areas in the two MOUD clinics for pregnant/postpartum
women and 2) in-person invitation by a research nurse. At an initial
prenatal visit in the buprenorphine clinic, clinic staff determines pa
tient’s smoking status. For all confirmed smokers, clinic staff assess their
willingness to receive study information from a research nurse. If the
patient is agreeable, a research nurse explains the purpose and proced
ures of the study, and determines initial eligibility for participation.
Women who are interested in participating and meet eligibility re
quirements are then taken through the informed consent process by a
research nurse prior to initiating any study procedures.

4.4. B-EPIC intervention
Women enrolled in the intervention group will receive TAU plus BEPIC, which includes four core components: 1) individualized tobacco
treatment plus supplemental counseling providing intensive support, 2)
change in maternal thought process and adoption of healthy behavior, in
accordance with the findings from our previous qualitative work [25,
26], 3) biomarker validation and feedback [28], and 4) pharmaco
therapy targeted at tobacco cessation as needed. See Table 3 for a
Table 1
Certified tobacco Treatment Specialists Core Competencies.

4.2. Randomization
Eligible participants are randomly assigned to one of two groups:
TAU tobacco treatment (control group) or B-EPIC group (tobacco
intervention) or. Participants are randomized to study group using SAS
PLAN (SAS Institute, Inc) that incorporates a stratification procedure
based on age (30+ verse less than 30). All participants continue to
receive opioid dependence treatment with buprenorphine integrated
with prenatal care, regardless of treatment assignment.

1
2
3
4
5
6
7
8

3

Tobacco dependence knowledge
Counseling and motivational interviewing skills
Assessment skills
Individualized treatment planning
Pharmacotherapy knowledge
Relapse prevention
Competence in working with diverse population subgroups
Referral resources for additional support
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Table 2
ACOG’s 5 A’s treatment as usual.

Table 4
B-EPIC intervention topicsa.

1. ASK the patient about smoking status at the 1st prenatal visit and follow-up with
her at subsequent visits.
2. ADVISE the patient who smokes to stop by providing advice to quit with
information about the risks of continued smoking to the woman, fetus, and
newborn.
3. ASSESS the patient’s willingness to attempt to quit smoking at the time. Quitting
advice, assessment, and motivational assistance should be offered at subsequent
visits.
4. ADVISE the patient who smokers to stop by providing advice to quit with
information about the risks of continued smoking to the woman, fetus, and
newborn.
5. ASSESS the patient’s willingness to attempt to quit smoking at the time. Quitting
advice, assessment, and motivational assistance should be offered at subsequent
visits.

•
•
•
•
•
•
•

Impact of smoking on pregnancy/fetal health
Impact of smoking on neonatal abstinence syndrome
Smoking cessation and long-term sobriety
Impact of smoking on women’s health
Effects of secondhand smoke on children
Financial cost of smoking
Smoking and COVID-19

a
Information presented to participants is tailored based on their personal
reasons for wanting to stop smoking.

empower women to adopt a smoke-free home environment to support
their cessation efforts and to avoid secondhand smoke exposure [25].
Perinatal Pharmacotherapy: According to the U.S. Preventive Ser
vices Task Force, nicotine replacement therapy has not been sufficiently
evaluated for safety or efficacy during pregnancy [29]. ACOG recom
mends that nicotine replacement therapy be used during pregnancy only
after a discussion of the risks of both continuing to smoke and of using
nicotine replacement therapy, under close medical supervision, and
with patients who express a strong desire to quit smoking [27]. The
CTTS provides clear information about the pharmacotherapy options
that are available (e.g, benefits, contraindications, and side effects) and
will communicate with the participant’s obstetrician about participant’s
interest in pharmacotherapy, if desired by the participant.

summary of the study visits and the components of each visit for the TAU
and B-EPIC groups. The initial assessment for this intervention takes 60
min, with follow-up sessions typically lasting 15–20 min. All sessions
occur prior to or after pre-scheduled perinatal appointments.
The intervention will be led by a research nurse who is certified as a
certified tobacco treatment specialist (CTTS). A CTTS is a professional
who possesses the skills, knowledge and training to provide effective,
evidence-based interventions for tobacco dependence across a range of
intensities. CTTS’s are trained in core competencies for the delivery of
tobacco dependence treatment consistent with established evidence (see
Table 1 for CTTS core competencies). Assessment, motivational coun
seling, and treatment planning (for both cessation and relapse), which
are tailored to the unique needs of tobacco users, are core skills used in
the delivery of CTTS services. Based on the CTTS assessment, inter
vention materials are tailored based on each woman’s individual rea
sons for being interested in smoking cessation (Table 4). Further, in
accordance with the model guiding this study, CTTS’s are trained to

5. Measures
A major strength of this study is its wide range of health and eco
nomic outcomes assessed on mother, neonate and the infant.

Table 3
Summary of study visits.
Time points

B-EPIC -Taking Action

Treatment as Usual

Outcomes

Baseline (up to 32
weeks)

• ACOG recommended 5A’s conducted by healthcare provider
• Individualized tobacco treatment sessions with CTTS (every monthminimum) plus supplemental counseling as desired (based on model,
see Fig. 1)
• Biomarker validation and feedback
• CTTS will discuss pharmacotherapy with healthcare provider if desired
by participant

ACOG recommended 5A’s
conducted by healthcare provider

•
•
•
•

3rd trimester
(28–36.6 weeks)

After Delivery of
Baby (2–8.6 weeks)

After Delivery of
Baby (20–28.6
weeks)

Incentives

Prenatal History
Demographics
Survey
Biomarkers

$20 gift
card

• Prenatal History
• Survey
• Biomarkers

$20 gift
card

• Labor and Birth
History
• Newborn History
• Survey
• Biomarkers
• Maternal and Infant
Outcomes
• Survey
• Biomarkers

$40 gift
card

$40 gift
card

Note: American College of Obstetricians and Gynecologists (ACOG); Certified Tobacco Treatment Specialist (CTTS); if all four study visits are completed, participant
receives an additional $20 gift card; Survey covers demographics, prenatal history, self-report tobacco use, nicotine dependence, secondhand smoke exposures, selfrecall substance use, recovery capital, perceived stress, adverse childhood events, anxiety, and depression.
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5.1. Primary outcomes

For Aim 3, the economic analysis will combine outcomes data from
Aim 2 (gestational age, birthweight) with cost data (direct and indirect
program costs, infant health services utilization) to assess incremental
cost effectiveness from a health system/payer perspective. Direct pro
gram costs will include personnel time directly associated with inter
vention delivery, including logged staff time and travel, but also pro rata
portions of supervision and office costs and any other costs that may be
associated with care delivery (e.g. printed materials). Indirect program
costs will include personnel time, materials, or facilities associated with
general program development and operations. This will be derived from
grant budgets and information supplied by community partners. Health
services utilization (e.g. physician office visit, emergency department
visit, hospitalization) will be costed out using average payment rates for
these services, by age, gender and year (source: Medical Expenditure
Panel Survey). Any facility usage (square feet) will be converted to an
imputed rent amount, using local rental rates (per square foot) for office
properties in the same zip code. This offers a conservative (high) esti
mate of the cost of space and represents the opportunity cost of the
space. Personnel time will be converted into monetary costs using
actual wage rates available through grant budgets or Bureau of Labor
Statistics (BLS) area wage surveys. To facilitate translation of our results
to other settings while maintaining privacy, our publications will sum
marize labor cost data by category (direct program, indirect program,
participant) and subcategory (e.g. faculty, staff, participant), and
include information on both time (in hours) and average hourly wage
rates.
The within-trial, incremental cost effectiveness ratio will be
computed as the ratio of the (1) difference in costs (B-EPIC group minus
TAU group) and (2) the difference in clinical outcomes. Separate esti
mates will be generated for each outcome measure (gestational age,
birthweight). We will also conduct sensitivity analyses where we
dichotomize outcomes (preterm, low birth weight). All estimates of costs
will be adjusted for inflation and transformed to net present value using
an annual discount rate. The results of this exploratory economic anal
ysis will provide critical preliminary data that will be used to estimate
the statistical power for a larger future study.

The primary outcomes for Aim 1 are smoking cessation, decrease in
number of cigarettes smoked per day, and readiness to quit smoking.
Smoking cessation is defined as a urine cotinine assay <100 ng/mL.
Cotinine is a metabolite of nicotine and has a half-life of approximately
9 h in pregnant women [30]. A commercial urine assay, NicAlert ®, with
cut-off limits of urine cotinine levels is a valid assay to measures urine
cotinine levels and to verify conventional cigarette use. Cigarettes per
day is measured via self-report on a survey. Readiness to quit is
measured using a ladder scale with ten options to indicate an in
dividual’s readiness to quit smoking [24].
The primary outcomes for Aim 2 are gestational age at birth, birth
weight, NAS diagnosis and severity, and number of ear and respiratory
infections during the first 5–6 months of age. All these data will be
collected via medical record review or by linking to Kentucky Medicaid
claims data. Gestational age at birth is defined as age in weeks on de
livery day, based on estimated weeks at first ultrasound. Birthweight is
defined as the first infant weight on day of delivery in grams. NAS
severity is determined based on the modified Finnegan Scale [31]. The
International Statistical Classification of Diseases and Related Health
Problems (typically abbreviated as ICD) diagnostic codes will be
collected from well-child and sick visits and hospital admissions and
re-admissions to determine ear and respiratory infections (e.g, tinnitus
unspecified is code 388.30).
The primary outcomes for Aim 3 are hospitalizations, hospital days,
NICU days, ED visits and sick-child outpatient visits for infants. These
data will be collected primarily from Kentucky Medicaid claims data,
with supplementary information from the medical record (for nonMedicaid study participants).
5.2. Data analysis
Descriptive analysis, including means, standard deviations and fre
quency distribution summarize all study outcomes. Baseline character
istics between the intervention group and the control, and between
those who complete the study and those who drop out will be examined
for potential covariates. These comparisons will be done using t-sample
t-tests, Mann-Whitney U tests, or chi-square tests of association, and
significant outcomes will be used as covariates in the following analyses.
Primary outcomes to be compared between treatment groups will
include tobacco indicators, such as smoking and illicit drug use status
(abstinence via urine cotinine) smoking frequency and readiness to quit
(cigarettes per day and stages of change), and maternal-child measures
(gestational age of birth, birthweight, NAS, NAS severity, early child
hood respiratory and ear infections). The collected variables will include
not only these primary outcomes and covariates, but also feasibility
indicators, such as average number of sessions completed and satisfac
tion ratings of the intervention by participants randomized to the
intervention group. We will also make group comparisons between
other variables that may affect maternal-child outcomes, including
second hand smoke (SHS) exposure, infant feeding status at discharge
(breastfeeding vs. formula), and number of people smoking in the home.
The continuous outcomes for the first two study aims will be analyzed
with a two-factor (group x time) repeated measures mixed model.
Generalized estimating equation (GEE), analyses with an exchangeable
correlation structure will assess for significant differences between
groups and across time for categorical and dichotomous outcomes (e.g.,
preterm birth, NAS) using the SAS GENMOD procedure. The main ef
fects of group and time and the interaction between them will be
included in each model, and covariates will be added to control for
group differences. As appropriate, post-hoc pairwise comparisons will
be calculated using Fisher’s least significant difference procedure for
mixed models and using contrast statements for GEE models. All ana
lyses will be conducted using SAS 9.4 (SAS Institute, Inc) and considered
significant at p ≤ 0.05.

5.3. Sample size
Sample size for this project was premised with a power of 0.8, alpha
= 0.05 and medium effect sizes. These assumptions were based upon
previous studies conducted with similar experimental designs and out
comes. With at least 30 mother/baby dyads completing the study per
group and an alpha level of 0.05, the power of the repeated measures
analysis of variance F test to detect a significant main for group will be
79%, assuming a medium effect size, while the power of the F tests to
detect a significant main effect of time or group by time interaction will
be at least 95%. In a preliminary study of this population by our group
(EMPOWR), we found that 14% of pregnant women decreased their
cigarette consumption between intake (typically during the second
trimester) and the third trimester. While smoking cessation is the ulti
mate goal of this intervention, prior research has demonstrated that
cutting cigarette consumption below 8 cigarettes per day is a risk
reduction strategy for preventing low birthweight, so we will consider
outcomes of both successful cessation as well as reduction in con
sumption for this project. Analysis of these power estimates indicates
that 100 subjects (50 per group) completing the proposed study will be
sufficient to detect significant main effects of treatment group.
6. Discussion
This study has several innovative features. First, the B-EPIC inter
vention is based on a novel theoretical framework developed by the
Principal Investigators based on previous qualitative work among
pregnant and postpartum tobacco and opioid dependent women,
including those receiving buprenorphine treatment. Second, this
5
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feasibility study has the potential to lead to a larger, multi-site trial
intervention, which if successful, would have the capacity to shift clin
ical practice paradigms to give specific emphasis on tobacco use rather
than letting it fall into general group discussions on illicit substance use
and psychosocial issues. Current standard of care does not prioritize
tobacco treatment for pregnant women with OUD. Due to time con
straints on clinicians, and the complex issues facing many women with
substance use disorders, tobacco often does not receive priority of
attention. Third, we are conducting a comprehensive evaluation of this
major public health issue, including a wide-range of maternal, neonatal,
and infant health outcomes, as well as associated healthcare costs and
cost effectiveness of the B-EPIC intervention.
There is a high likelihood of adoption, scalability and sustainability
of B-EPIC in clinical practice settings for two primary reasons. First, The
B-EPIC intervention was designed to be integrated into programs
providing comprehensive treatment for OUD, including buprenorphine,
and across the country, there are a growing number of buprenorphine
providers (e.g., over 111,000 providers who are waivered to provide
buprenorphine) [32]. Second, the intervention relies on CTTS, who are
providing billable services that are reimbursed from private and public
insurers, and there are CTTS training programs available across the
country in-person and via virtual platforms [33].
Limitations. This study also has several limitations. First, the validity
of the FTND may vary across sex, gender and race/ethnicity [34,35].
Additionally, some healthcare providers have concerns that using urine
cotinine to validate smoking status may their clinical relationship with
their patients [36]. However, pregnant and postpartum women who
smoked before or during pregnancy have reported that point-of-care
cotinine testing had benefits, including encouraging conversations
around tobacco cessation [36]. Further, in order to rigorously evaluate
the impact of the intervention on smoking outcomes, it is necessary to
verify smoking status. Previous research indicates that more than 25% of
pregnant and postpartum women did not disclose tobacco use but had a
positive urine cotinine screening [37].
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